Roche aims to boost genetic testing offering with $5.7bn Illumina hostile takeover bid
This article was originally published in Clinica
Executive Summary
Roche has made a $5.7bn hostile takeover bid for gene sequencing market leader Illumina, in an effort to consolidate its number-one position in the diagnostics market and boost its presence in the genetic testing sector.